Zevra Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Zevra Therapeutics

05/05/2025 21:13

Zevra Therapeutics Inc ZVRA.OQ ZVRA.O is expected to show a rise in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The Celebration Florida-based  company is expected to report a 395.1% increase in revenue to $16.958 million from $3.43 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Zevra Therapeutics Inc is for a loss of 19 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Zevra Therapeutics Inc is $22.00​, above​ its last closing price of $8.00. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.40
-0.40
-0.69
Missed
-70.7
Sep. 30 2024
-0.42
-0.42
-0.69
Missed
-63.8
Jun. 30 2024
-0.44
-0.43
-0.48
Missed
-10.6​
Mar. 31 2024
-0.48
-0.48
-0.40
Beat
16.3
​​Dec. 31 2023
-0.19
-0.27
-0.40
Missed
-49.1
Sep. 30 2023
-0.30
-0.30
-0.40
Missed
-34.5​
Jun. 30 2023
-0.37
-0.34
-0.15
Beat
56.3
Mar. 31 2023
-0.24
-0.23
-0.34
Missed
-46.2

This summary was machine generated May 5 at 20:13 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)